PepGen (PEPG) Projected to Post Earnings on Monday

PepGen (NASDAQ:PEPG) is anticipated to release its Q4 2025 results before the market opens on Monday, February 23rd. Analysts expect PepGen to post earnings of ($0.38) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.

PepGen Price Performance

NASDAQ PEPG opened at $6.22 on Friday. PepGen has a 12 month low of $0.88 and a 12 month high of $7.80. The company has a market capitalization of $427.63 million, a P/E ratio of -2.21 and a beta of 1.91. The company’s 50 day simple moving average is $5.76 and its 200 day simple moving average is $4.38.

Analyst Upgrades and Downgrades

PEPG has been the subject of a number of recent research reports. Guggenheim increased their price objective on PepGen from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Wednesday. HC Wainwright boosted their target price on PepGen from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Wall Street Zen upgraded PepGen from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of PepGen in a research note on Thursday, January 22nd. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC purchased a new stake in PepGen in the 1st quarter worth approximately $122,000. Woodline Partners LP purchased a new stake in shares of PepGen during the first quarter worth $1,097,000. Marshall Wace LLP acquired a new stake in PepGen during the second quarter valued at $44,000. Qube Research & Technologies Ltd acquired a new stake in PepGen during the second quarter valued at $81,000. Finally, Bridgeway Capital Management LLC grew its stake in PepGen by 61.5% in the second quarter. Bridgeway Capital Management LLC now owns 91,923 shares of the company’s stock valued at $102,000 after purchasing an additional 35,000 shares in the last quarter. Institutional investors and hedge funds own 58.01% of the company’s stock.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).